Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Mittendorf EA"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 29
Tytuł:
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Autorzy:
Mittendorf EA
Clifton GT
Holmes JP
Clive KS
Patil R
Benavides LC
Gates JD
Sears AK
Stojadinovic A
Ponniah S
Peoples GE
Mittendorf, Elizabeth A
Clifton, Guy T
Holmes, Jarrod P
Clive, Kevin S
Patil, Ritesh
Benavides, Linda C
Gates, Jeremy D
Sears, Alan K
Stojadinovic, Alexander
Pokaż więcej
Źródło:
Cancer (0008543X); May2012, Vol. 118 Issue 10, p2594-2602, 9p
Czasopismo naukowe
Szczegóły
Tytuł:
Inequities in referrals to a breast cancer risk assessment and prevention clinic: a mixed methods study.
Autorzy:
King CB; Comprehensive Breast Health Center, Brigham and Women's Hospital, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Bychkovsky BL; Comprehensive Breast Health Center, Brigham and Women's Hospital, Boston, MA, USA.; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Warner ET; Harvard Medical School, Boston, MA, USA.; Massachusetts General Hospital, Boston, MA, USA.
King TA; Comprehensive Breast Health Center, Brigham and Women's Hospital, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Freedman RA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Mittendorf EA; Comprehensive Breast Health Center, Brigham and Women's Hospital, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Katlin F; Comprehensive Breast Health Center, Brigham and Women's Hospital, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Revette A; Division of Population Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Crookes DM; Department of Health Sciences, Northeastern University, Boston, MA, USA.; Department of Sociology and Anthropology, Northeastern University, Boston, MA, USA.
Maniar N; Department of Health Sciences, Northeastern University, Boston, MA, USA.
Pace LE; Comprehensive Breast Health Center, Brigham and Women's Hospital, Boston, MA, USA. .; Harvard Medical School, Boston, MA, USA. .; Division of Women's Health, Brigham and Women's Hospital, Boston, MA, USA. .
Pokaż więcej
Źródło:
BMC primary care [BMC Prim Care] 2023 Aug 25; Vol. 24 (1), pp. 165. Date of Electronic Publication: 2023 Aug 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms*/diagnosis
Breast Neoplasms*/epidemiology
Breast Neoplasms*/prevention & control
United States/epidemiology ; Humans ; Aged ; Female ; Medicare ; Breast ; Referral and Consultation ; Risk Assessment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial.
Autorzy:
Abuhadra N; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sun R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yam C; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rauch GM; Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ding Q; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lim B; Department of Oncology, Baylor College of Medicine, Houston, TX 77030, USA.
Thompson AM; Division of Surgical Oncology, Section of Breast Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Mittendorf EA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
Adrada BE; Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Damodaran S; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Virani K; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
White J; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ravenberg E; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sun J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Choi J; Department of Statistics, Rice University, Houston, TX 77005, USA.
Candelaria R; Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Arun B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ueno NT; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Santiago L; Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Saleem S; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abouharb S; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Murthy RK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ibrahim N; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sahin A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Valero V; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Symmans WF; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Moulder S; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Huo L; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Jun 21; Vol. 15 (13). Date of Electronic Publication: 2023 Jun 21.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Metabolic abnormalities and survival among patients with non-metastatic breast cancer.
Autorzy:
Zimbalist AS; Division of Research, Kaiser Permanente Northern California, 2000 Broadway, 5Th Floor, Oakland, CA, 94612, USA.
Caan BJ; Division of Research, Kaiser Permanente Northern California, 2000 Broadway, 5Th Floor, Oakland, CA, 94612, USA.
Chen WY; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02215, USA.
Mittendorf EA; Division of Breast Surgery, Brigham and Women's Hospital, Boston, MA, 02215, USA.; Breast Oncology, Dana-Farber Brigham Cancer Center, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, 02215, USA.
Dillon DAR; Harvard Medical School, Boston, MA, 02215, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Quesenberry C; Division of Research, Kaiser Permanente Northern California, 2000 Broadway, 5Th Floor, Oakland, CA, 94612, USA.
Cespedes Feliciano EM; Division of Research, Kaiser Permanente Northern California, 2000 Broadway, 5Th Floor, Oakland, CA, 94612, USA. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Dec 29; Vol. 22 (1), pp. 1361. Date of Electronic Publication: 2022 Dec 29.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/therapy
Diabetes Mellitus*
Humans ; Female ; Middle Aged ; Cholesterol, LDL ; Risk Factors ; Triglycerides ; Cholesterol, HDL ; Glucose
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.
Autorzy:
Burton EM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .
Amaria RN; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cascone T; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chalabi M; Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Gross ND; Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mittendorf EA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital/Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Scolyer RA; Melanoma Institute of Australia, The University of Sydney/Faculty of Medicine and Health, The University of Sydney/Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology/Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Sharma P; Immunotherapy Platform, Department of Immunology/Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2022 Jun 15; Vol. 20 (1), pp. 271. Date of Electronic Publication: 2022 Jun 15.
Typ publikacji:
Congress
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Melanoma*/pathology
Humans ; Immunotherapy ; Male ; Neoadjuvant Therapy
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx Digital Spatial Profiler.
Autorzy:
Bergholtz H; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, 0450 Oslo, Norway.
Carter JM; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Cesano A; ESSA Pharma Inc., South San Francisco, CA 94080, USA.
Cheang MCU; ICR Clinical Trials and Statistics Unit, Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK.
Church SE; NanoString® Technologies Inc., Seattle, WA 98109, USA.
Divakar P; NanoString® Technologies Inc., Seattle, WA 98109, USA.
Fuhrman CA; NanoString® Technologies Inc., Seattle, WA 98109, USA.
Goel S; Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.
Gong J; NanoString® Technologies Inc., Seattle, WA 98109, USA.
Guerriero JL; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
Hoang ML; NanoString® Technologies Inc., Seattle, WA 98109, USA.
Hwang ES; Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
Kuasne H; Rosalind and Morris Goodman Cancer Centre, McGill University, Montreal, QC H3A 0G4, Canada.
Lee J; Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.
Liang Y; NanoString® Technologies Inc., Seattle, WA 98109, USA.
Mittendorf EA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Harvard Medical School, Boston, MA 02115, USA.
Perez J; NanoString® Technologies Inc., Seattle, WA 98109, USA.
Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, 08036 Barcelona, Spain.
Pusztai L; Yale Cancer Center, Yale School of Medicine, New Haven, CT 06510, USA.
Reeves JW; NanoString® Technologies Inc., Seattle, WA 98109, USA.
Riazalhosseini Y; Department of Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada.; McGill University Genome Centre, McGill University, Montreal, QC H3A 0G4, Canada.
Richer JK; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Sahin Ö; Department of Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, SC 29208, USA.
Sato H; NanoString® Technologies Inc., Seattle, WA 98109, USA.
Schlam I; MedStar Washington Hospital Center, Washington, DC 20010, USA.; Tufts Medical Center, Boston, MA 02111, USA.
Sørlie T; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, 0450 Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Stover DG; Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Swain SM; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA.; Georgetown University Medical Center, Washington, DC 20057, USA.; MedStar Health, Washington, DC 20057, USA.
Swarbrick A; Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney NSW 2052, Australia.
Thompson EA; Department of Cancer Biology, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
Tolaney SM; Harvard Medical School, Boston, MA 02115, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Warren SE; NanoString® Technologies Inc., Seattle, WA 98109, USA.
On Behalf Of The GeoMx Breast Cancer Consortium
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Sep 04; Vol. 13 (17). Date of Electronic Publication: 2021 Sep 04.
Typ publikacji:
Guideline
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer.
Autorzy:
Akay CL; Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Albarracin C; Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Torstenson T; Department of Surgery at the Mercy Medical Center, Des Moines, IA, USA.
Bassett R; Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Mittendorf EA; Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Yi M; Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Kuerer HM; Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Babiera GV; Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Bedrosian I; Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Hunt KK; Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Hwang RF; Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
The breast journal [Breast J] 2018 Jan; Vol. 24 (1), pp. 28-34. Date of Electronic Publication: 2017 Jun 13.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Breast Neoplasms/*pathology
Neoadjuvant Therapy/*statistics & numerical data
Sentinel Lymph Node/*pathology
Sentinel Lymph Node Biopsy/*standards
Adult ; Aged ; Aged, 80 and over ; Case-Control Studies ; Female ; Humans ; Lymph Node Excision ; Lymphatic Metastasis/pathology ; Middle Aged ; Neoplasm Grading/methods ; Predictive Value of Tests ; Prospective Studies ; Receptor, ErbB-2/metabolism ; Sentinel Lymph Node Biopsy/methods ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.
Autorzy:
McAuliffe PF
Evans KW
Akcakanat A
Chen K
Zheng X
Zhao H
Eterovic AK
Sangai T
Holder AM
Sharma C
Chen H
Do KA
Tarco E
Gagea M
Naff KA
Sahin A
Multani AS
Black DM
Mittendorf EA
Bedrosian I
Mills GB
Gonzalez-Angulo AM
Meric-Bernstam F
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Mar 08; Vol. 11 (3), pp. e0151121. Date of Electronic Publication: 2016 Mar 08 (Print Publication: 2016).
Typ publikacji:
Published Erratum
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.
Autorzy:
McAuliffe PF; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Akcakanat A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Chen K; Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Zheng X; Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Zhao H; Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Eterovic AK; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Sangai T; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Holder AM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Sharma C; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Chen H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Do KA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Tarco E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Gagea M; Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Naff KA; Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Sahin A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Multani AS; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Black DM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Mittendorf EA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Bedrosian I; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Mills GB; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Gonzalez-Angulo AM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Meric-Bernstam F; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Sep 01; Vol. 10 (9), pp. e0136851. Date of Electronic Publication: 2015 Sep 01 (Print Publication: 2015).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms/*pathology
Drug Resistance, Neoplasm/*physiology
Heterografts/*pathology
Adult ; Aged ; Aged, 80 and over ; Animals ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Chemotherapy, Adjuvant/methods ; Disease-Free Survival ; Drug Resistance, Neoplasm/drug effects ; Female ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Middle Aged ; Neoadjuvant Therapy/methods ; Neoplasm Recurrence, Local/pathology ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
Autorzy:
Melo SA; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
Luecke LB; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
Kahlert C; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
Fernandez AF; Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), HUCA, Universidad de Oviedo, 33006 Oviedo, Spain.
Gammon ST; Department of Cancer Systems Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77054, USA.
Kaye J; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
LeBleu VS; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
Mittendorf EA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Weitz J; Department of Gastrointestinal, Thoracic and Vascular Surgery, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
Rahbari N; Department of Gastrointestinal, Thoracic and Vascular Surgery, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
Reissfelder C; Department of Gastrointestinal, Thoracic and Vascular Surgery, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
Pilarsky C; Department of Gastrointestinal, Thoracic and Vascular Surgery, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
Fraga MF; 1] Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), HUCA, Universidad de Oviedo, 33006 Oviedo, Spain [2] Department of Immunology and Oncology, National Center for Biotechnology, CNB-CSIC, Cantoblanco, 28049 Madrid, Spain.
Piwnica-Worms D; Department of Cancer Systems Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77054, USA.
Kalluri R; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
Pokaż więcej
Źródło:
Nature [Nature] 2015 Jul 09; Vol. 523 (7559), pp. 177-82. Date of Electronic Publication: 2015 Jun 24.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Glypicans*/blood
Glypicans*/metabolism
Exosomes/*metabolism
Pancreatic Neoplasms/*diagnosis
Animals ; Biomarkers/blood ; Cell Line, Tumor ; Exosomes/genetics ; Female ; HCT116 Cells ; Humans ; MCF-7 Cells ; Male ; Mice ; NIH 3T3 Cells ; Pancreatic Neoplasms/blood ; Pancreatic Neoplasms/pathology ; Proto-Oncogene Proteins/metabolism ; Proto-Oncogene Proteins p21(ras) ; ras Proteins/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Consensus nomenclature for CD8 T cell phenotypes in cancer.
Autorzy:
Apetoh L; INSERM; UMR 866 , Dijon, France ; Centre Georges François Leclerc , Dijon, France ; Université de Bourgogne , Dijon, France.
Smyth MJ; QIMR Berghofer Medical Research Institute , Herston, Queensland, Australia.
Drake CG; Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University School of Medicine , Baltimore, MD, USA.
Abastado JP; Institut de Recherches Internationales Servier ; 53, rue Carnot , Suresnes, France.
Apte RN; The Shraga Segal Department of Microbiology; Immunology and Genetics ; The Faculty of Health Sciences, Ben Gurion University of the Negev , Beer Sheva, Israel.
Ayyoub M; INSERM, Unité1102; Equipe Labellisée Ligue Contre le Cancer ; Institut de Cancérologie de l'Ouest , Nantes-Saint Herblain; France.
Blay JY; Cancer Research Center of Lyon; INSERM UMR 1052 ; CNRS UMR 5286 , Centre Leon Berard, Lyon, France ; Medical Oncology Department , Lyon, France.
Bonneville M; CRCNA, INSERM U892; CNRS UMR 6299 , Nantes, France ; Institut Mérieux , Lyon, France.
Butterfield LH; University of Pittsburgh Cancer Institute, Departments of Medicine, Surgery, and Immunology , Pittsburgh, PA, USA.
Caignard A; INSERM UMR 1116 , Paris, France.
Castelli C; Unit of Immunotherapy of Human Tumor; Department of Experimental Oncology and Molecular Medicine ; Fondazione IRCCS Istituto Nazionale dei Tumori , Milan, Italy.
Cavallo F; Department of Molecular Biotechnology and Health Sciences; Molecular Biotechnology Center, University of Torino , Italy.
Celis E; Cancer Immunology; Inflammation and Tolerance Program; Georgia Regents University Cancer Center ; Augusta, GA, USA.
Chen L; Department of Immunobiology and Yale Cancer Center; Yale University School of Medicine , New Haven, CT, USA.
Colombo MP; Molecular Immunology Unit; Department of Experimental Oncology and Molecular Medicine ; Fondazione IRCCS Istituto Nazionale dei Tumori ; Milan, Italy.
Comin-Anduix B; UCLA School of Medicine ; Jonsson Comprehensive Cancer Center Los Angeles , CA, USA.
Coukos G; Ludwig Center for Cancer Research; Department of Oncology; University of Lausanne , Switzerland.
Dhodapkar MV; Department of Immunobiology and Yale Cancer Center; Yale University School of Medicine , New Haven, CT, USA.
Dranoff G; Department of Medical Oncology and Cancer Vaccine Center; Dana-Farber Cancer Institute and Department of Medicine ; Brigham and Women's Hospital and Harvard Medical School , Boston, MA, USA.
Frazer IH; The University of Queensland , Queensland, Australia.
Fridman WH; Cordeliers Research Centre, University of Paris-Descartes , Paris, France.
Gabrilovich DI; Translational Tumor Immunology; The Wistar Institute , Philadelphia, PA, USA.
Gilboa E; Department of Microbiology & Immunology; Dodson Interdisciplinary Immunotherapy Institute ; Sylvester Comprehensive Cancer Center; Miller School of Medicine ; University of Miami , Miami, FL, USA.
Gnjatic S; Tisch Cancer Institute; Icahn School of Medicine at Mount Sinai , New York, NY, USA.
Jäger D; Department of Medical Oncology; National Center for Tumor Diseases ; Internal Medicine VI; Heidelberg University Hospital , Heidelberg, Germany.
Kalinski P; Department of Surgery; University of Pittsburgh ; Pittsburgh, PA, USA.
Kaufman HL; Rutgers Cancer Institute of New Jersey , New Brunswick, NJ, USA.
Kiessling R; Department of Oncology/Pathology; Karolinska Institutet , Stockholm, Sweden.
Kirkwood J; Division of Hematology/Oncology; Department of Medicine ; School of Medicine; University of Pittsburgh , Pittsburgh; PA; USA ; Melanoma and Skin Cancer Program; University of Pittsburgh Cancer Institute , Pittsburgh, PA, USA.
Knuth A; National Center for Cancer Care & Research , Doha, Qatar.
Liblau R; INSERM-UMR 1043 ; Toulouse, France ; CNRS ; U5282 , Toulouse, France ; Universite de Toulouse; UPS ; Centre de Physiopathologie Toulouse Purpan (CPTP) ; Toulouse, France ; CHU Toulouse Purpan ; Toulouse, France.
Lotze MT; Hillman Cancer Center; University of Pittsburgh Schools of Health Sciences , Pittsburgh, PA, USA.
Lugli E; Unit of Clinical and Experimental Immunology; Humanitas Clinical and Research Center , Rozzano, Italy.
Marincola F; Research Branch; Sidra Medical and Research Centre , Doha, Qatar.
Melero I; Division of Oncology; Center for Applied Medical Research and Clinica Universidad de Navarra , Pamploma, Spain.
Melief CJ; Leiden University; ISA Pharmaceuticals , Netherlands.
Mempel TR; Center for Immunology and Inflammatory Diseases; Massachusetts General Hospital ; Harvard Medical School , Boston, MA, USA.
Mittendorf EA; Deparment of Surgical Oncology; University of Texas MD Anderson Cancer Center , Houston, TX, USA.
Odun K; Departments of Gynecologic Oncology and Immunology; Roswell Park Cancer Institute , Buffalo, NY, USA.
Overwijk WW; Department of Melanoma Medical Oncology; University of Texas MD Anderson Cancer Center , Houston, TX, USA.
Palucka AK; The Jackson Laboratory for Genomic Medicine , Farmington, CT, USA.
Parmiani G; Division of Medical Oncology and Immunotherapy; University Hospital , Siena, Italy.
Ribas A; UCLA School of Medicine ; Jonsson Comprehensive Cancer Center Los Angeles , CA, USA.
Romero P; Ludwig Center for Cancer Research; Department of Oncology; University of Lausanne , Switzerland.
Schreiber RD; Department of Pathology and Immunology; Washington University School of Medicine , St. Louis, MO USA.
Schuler G; Department of Dermatology; Universitatsklinikum Erlangen , Erlangen, Germany.
Srivastava PK; Center for Immunotherapy of Cancer and Infectious Diseases; Carole and Ray Neag Comprehensive Cancer Center ; University of Connecticut Health Center , Farmington, CT, USA.
Tartour E; Department of Clinical Oncology, INSERM U970; Universite Paris Descartes ; Sorbonne Paris-Cité; Paris ; France; Hôpital Européen Georges Pompidou ; Service d'Immunologie Biologique ; Paris, France.
Valmori D; INSERM, Unité1102; Equipe Labellisée Ligue Contre le Cancer ; Institut de Cancérologie de l'Ouest , Nantes-Saint Herblain; France ; Faculty of Medicine, University of Nantes, 44035 Nantes, France.
van der Burg SH; Leiden University Medical Center , Leiden, Netherlands.
van der Bruggen P; Ludwig Institute for Cancer Research; BrusselsBranch de Duve Institute ; Université Catholique de Louvain , Brussels, Blegium.
van den Eynde BJ; Ludwig Institute for Cancer Research; BrusselsBranch de Duve Institute ; Université Catholique de Louvain , Brussels, Blegium.
Wang E; Research Branch; Sidra Medical and Research Centre , Doha, Qatar.
Zou W; Department of Surgery; University of Michigan School of Medicine , Ann Arbor , MI, USA.
Whiteside TL; Department of Pathology; Immunology, and Otolaryngology ; University of Pittsburgh Cancer Institute , Pittsburgh, PA, USA.
Speiser DE; Ludwig Center for Cancer Research; Department of Oncology; University of Lausanne , Switzerland.
Pardoll DM; Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University School of Medicine , Baltimore, MD, USA.
Restifo NP; National Cancer Institute; National Institutes of Health , Bethesda, MD, USA.
Anderson AC; Evergrande Center for Immunologic Diseases; Ann Romney Center for Neurologic Diseases ; Brigham and Women's Hospital and Harvard Medical School , Boston, MA USA.
Pokaż więcej
Źródło:
Oncoimmunology [Oncoimmunology] 2015 Feb 25; Vol. 4 (4), pp. e998538. Date of Electronic Publication: 2015 Feb 25 (Print Publication: 2015).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 29

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies